SCHEMBL5115968

SCHEMBL5115968

O=C(O)Cc1csc(-c2cc(Cl)ccc2OCc2ccc(Cl)cc2F)n1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 10/20 0.61
CYP2C9 P11712 5/20 0.50
CYP2C19 P33261 3/20 0.50
CYP1A2 P05177 2/20 0.50
TBXA2R P21731 2/20 0.50
PTGS1 P23219 2/20 0.50
PTGER3 P43115 2/20 0.50
PTGER2 P43116 2/20 0.50
CYP3A4 P08684 1/20 0.49
SHMT1 P34896 2/20 0.47
SHMT2 P34897 2/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5123623 0.95 PTGER1 (0.58) PTGER1CYP2C9CYP2C19CYP3A4KDM4E
SCHEMBL5121292 0.93 PTGER1 (0.60) PTGER1CYP2C9CYP2C19CYP1A2TBXA2R
SCHEMBL5119199 0.92 PTGER1 (0.64) PTGER1CYP2C9CYP2C19CYP3A4SHMT1
SCHEMBL5130647 0.89 PTGER1 (0.58) PTGER1CYP2C9CYP2C19CYP1A2CYP3A4
SCHEMBL14098714 0.87 PTGER1 (0.54) PTGER1CYP2C9CYP2C19CYP1A2TBXA2R
SCHEMBL5129850 0.87 PTGER1 (0.60) PTGER1CYP2C9CYP2C19TBXA2RCYP3A4
SCHEMBL5126953 0.87 PTGER1 (0.60) PTGER1TBXA2RSHMT1SHMT2KDM4E
SCHEMBL5125104 0.87 PTGER1 (0.66) PTGER1TBXA2RSHMT1SHMT2KDM4E
SCHEMBL4721023 0.85 PTGER1 (0.70) PTGER1CYP2C9TBXA2RPTGER3SHMT1
SCHEMBL5121721 0.85 PTGER1 (0.67) PTGER1TBXA2RSHMT1SHMT2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders GLAXO GROUP LIMITED (GB) 2008-08-28 US disclosed
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders GLAXO GROUP LIMITED (GB) 2008-08-28 US disclosed
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders GLAXO GROUP LIMITED (GB) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders PTGER1, PTGER2, PTGER4 PTGER1 1/4885CYP2C9 142/4885CYP2C19 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.